ArticleCost effectiveness and resource allocation : C/E2024

Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis.

Yilai Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.